look news india
Malaria, spread by mosquitoes, kills about 608,000 people worldwide every year. Now a new hope has arisen against this disease, because recently in a small clinical trial it has been found that a new vaccine has proved to be effective and safe in preventing malaria.
A genetically modified Plasmodium falciparum parasite called ‘GA2’ has been used for this vaccination. The results of this trial conducted by researchers from Leiden University Medical Center and Radboud University Medical Center in the Netherlands have proved that this vaccine can be very effective in fighting malaria and can provide protection against malaria.
Clinical Trial Results
The study involved 25 healthy adults, none of whom had previously been infected with malaria. Participants were vaccinated with a genetically modified P. falciparum parasite (GA2), which is designed to grow in the liver for a long time. During this trial, 10 participants were placed in the Ga2 group, 10 in the Ga1 group, and 5 in the placebo group. All three groups were vaccinated three times at 28-day intervals.
Next, participants in the GA2 and GA1 groups were exposed to mosquitoes infected with the P. falciparum parasite, while participants in the placebo group were exposed to uninfected mosquitoes. Finally, all participants were exposed to a controlled malaria infection to see how much protection the vaccine provided.
Vaccine effectiveness
The results of the study, published in the New England Journal of Medicine, found that 89% of participants in the GA2 group were protected against malaria. Only 13% of participants in the GA1 group got protection, and none in the placebo group got protection. This makes it clear that the GA2 vaccine provides a high level of protection against malaria.
Safe and effective vaccination
The special thing about this vaccine is that no participant in the GA2 group got malaria after vaccination, which proves that this vaccine is not only effective but also safe. The researchers also found that participants in the GA2 group had a stronger pro-inflammatory response, further strengthening the safety of this vaccination. Furthermore, both the GA2 and GA1 groups produced similar levels of antibodies, but GA2 provided additional protection, which was largely due to the response of the cellular immune system.
hope for times to come
This test can prove to be an important step against malaria. If the vaccine’s effectiveness is confirmed in larger future trials, it could become an important tool in the treatment and prevention of malaria. This new vaccine has emerged as a great hope to prevent the deadly disease malaria and could help reduce the impact of malaria on the global health system.